Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Grace Kong discussing the benefits ...
The first patient had extensive PSMA-avid disease at baseline and continued to demonstrate substantial disease on serial post ...
The Prostate Cancer Foundation framework summarizes five major components used for risk stratification: PSA level, tumor ...
The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Daniel Moon discussing the PRIMARY ...
Increasingly, 177 Lu-PSMA-617 is used for patients with mCRPC, while many of these patients may also require palliative ...
Data from this study demonstrated progressive reductions in estimated glomerular filtration rate (eGFR) over time following initiation of 177 Lu-PSMA-I&T therapy, with trajectories shown separately ...
Quantitative PSMA uptake was the third prognostic biomarker highlighted, with increasing SUVmean associated with an HR of 1.74. Patients were stratified according to quartiles of SUVmean, with ...
Using baseline clinical data alone, the model incorporated prior treatments, blood-test results, ECOG performance status, PSA ...
The 2026 ProsTIC annual meeting featured a Lutetium-177 session and a presentation by Dr. Renu Eapen discussing whether there ...
(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Sidney Levy ...
(UroToday.com) The 2026 ProsTIC annual meeting featured a Lutetium-177 session and a presentation by Dr. Arun Azad discussing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results